To Gain More Insights into the Familial Chylomicronemia Syndrome Treatment Market, Browse Summary of the Research Report –
Familial Chylomicronemia Syndrome is a genetic condition characterized by an inability of the body to digest fats mainly triglyceride. In Familial Chylomicronemia Syndrome, the lipoprotein lipase (LPS) is not functional, which is the enzyme that breaks down chylomicrons in the blood. Healthcare providers can clinically diagnosed FCS by looking for acute pancreatitis, abdominal pain, uncontrolled diabetes, excess alcohol intake and hypertriglyceridemia.
The most distinctive sign of Familial Chylomicronemia Syndrome is the appearance of fatty blood on the skin, mainly owing to high level of fat in the body. People with extremely high triglycerides levels are more subjected to FCS. According to the Familial Chylomicronemia Syndrome (FCS) Foundation report, in 2017, around 30 million people suffer from rare diseases, accounted for every 1 out of 10 people in the U.S, and also 95% of rare diseases have no Food and Drug Administration (FDA) approved treatment. Familial Chylomicronemia Syndrome is a rare disorder that affect small population worldwide. According to a report by National Organiztion for Rare Disorders (NORD), in 2017, FCS is more prevalent in French community and certain communities of the Netherland, where the prevalence is as high as every 19 to 20 per one million individuals.
https://www.coherentmarketinsights.com/ongoing-insight/familial-chylomicronemia-syndrome-treatment-market-946
Severe complications associated with FCS include fatty liver diseases, enlarged liver, enlarged spleen, and pancreatitis, which can be life-threatening. In pancreatitis, pancreas produces hormones insulin, which helps to digest food and regulates blood sugar level. It is characterized by inflammation of pancreas, which is extremely painful and can be severe. Frequent attacks of pancreatitis may lead to long-term organ damage or death. Due to the rarity of the condition, the clinical progression of this syndrome is not well understood, which is creating an opportunity for the Familial Chylomicronemia Syndrome treatment market player in near future.
“We Do Offer Sample of Familial Chylomicronemia Syndrome Treatment Market Report. Kindly go through the follow information in order to access sample copy.”
https://www.coherentmarketinsights.com/insight/request-sample/946
In people with FCS, the triglyceride level can increase up to 20 to 30 times as compared to normal individuals, even with medication of a low-fat diet. Researchers are working to develop a therapy with a potential to reduce the level of ApoC-III in the blood. ApoC-III has proven to be a protein that regulate triglycerides level in the human body. Thus, reducing the amount of ApoC-III may help to regulate the elevated levels of triglyceride, which is a significant risk factor for pancreatitis.
In September 2017, Akcea Therapeutics Inc., a subsidiary of Ionis Pharmaceutical Inc., announced the filing of New Drug Submission (NDS) to Health Canada for Volanesorsen with the focus to develop and commercialize drugs to treat severe cardio metabolic disease caused by lipid disorder.
Table of Contents
https://www.coherentmarketinsights.com/ongoing-insight/toc/946
Top players in the market
Glybera, a gene therapy, is designed to restore the LPL enzyme required to clear the fat-carrying chylomicron particles from the intestine. It is a one-time gene therapy treatment, which includes a series of 60 intramuscular injections in the legs. In October 2012, the European commission granted marketing authorization of Glybera under exceptional circumstances as a treatment for small subsets of adult patients diagnosed with familial LPL deficiency, which was confirmed by genetic testing. In April 2017, uniQure announced non-renewal of Glybera gene therapy authorization in Europe, which is scheduled to expire in October 2017. The non-renewal of Glybera’s marketing authorization in Europe is expected to affect the overall market of FCS.
Research methodology adopted by Coherent Market Insights
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
• Primary Research (Trade Surveys and Experts Interviews)
• Desk Research
• Proprietor Data Analytics Model
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Request A Sample Copy Familial Chylomicronemia Syndrome Treatment Market Report Click here:
https://www.coherentmarketinsights.com/insight/request-sample/946
Get PDF Research Report Brochure @
https://www.coherentmarketinsights.com/insight/request-pdf/946
Buy Now this Premium Report to Grow your Business @
https://www.coherentmarketinsights.com/insight/buy-now/946
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.
Contact Us:
Name: Mr. Raj Shah
Email: [email protected]
Phone: US +12067016702
Country: United States
Visit our Blog: https://hospitalhealthcareblog.wordpress.com/